Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Validive, a specialized clonidine hydrochloride mucobuccal tablet, is currently undergoing Phase 2b/3 clinical trials. This therapy aims to prevent severe oral mucositis, a debilitating side effect of chemoradiotherapy, in patients suffering from oropharyngeal cancer. The company's pipeline also includes Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for advanced soft tissue sarcoma. Furthermore, Monopar is developing MNPR-101, an antibody engineered to target the urokinase plasminogen activator receptor (uPAR) for various cancer indications. A radioimmunotherapeutic variant of MNPR-101, named MNPR-101 RIT, is being explored for its potential in both cancer therapy and the treatment of severe COVID-19. Another promising compound, MNPR-202, an analog of camsirubicin, is being developed to potentially address cancers that have developed resistance to doxorubicin and camsirubicin. Monopar Therapeutics Inc. maintains strategic partnerships, including one with the Grupo Español de Investigación en Sarcomas (GEIS) for the advancement of camsirubicin in patients with advanced soft tissue sarcoma. They also collaborate with NorthStar Medical Radioisotopes, LLC on the development of radio-immunotherapeutics targeting severe COVID-19, and with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related compounds across different cancer types. The company was established in 2014 and its corporate headquarters are situated in Wilmette, Illinois.
zacks.comWall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Tradezacks.comJun 15
globenewswire.comMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026globenewswire.comJun 1
globenewswire.comMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Diseaseglobenewswire.comMay 19
globenewswire.comMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.comMay 14
globenewswire.comMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026globenewswire.comApr 19